In This Article:
The Company Invites Investors, Industry Executives, and Analysts to Attend Its Real-time, Interactive Presentation
SAN DIEGO, CA - February 18, 2025 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a developer of next-generation blood purification therapies to address cancer and life-threatening infectious disease disorders, today announced that Jim Joyce, the Company's CEO, will give a live presentation at tomorrow's Emerging Growth Conference.
Date: February 19th
Time: 4:10pm 4:40pm Eastern
Registration: https://goto.webcasts.com/starthere.jsp?ei=1696664&tp_key=a17d7ff4c2&sti=sigy
This will be a live, interactive online event where participants are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.
About Sigyn Therapeutics(TM)
Sigyn Therapeutics is developing next-generation blood purification therapies to address cancer and life-threatening infectious disease disorders that are not treatable with drugs. The Company's lead product candidate, Sigyn Therapy(TM) has been demonstrated to reduce the presence of viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma. Based on these capabilities, Sigyn Therapy(TM) is a candidate to treat life-threatening viral pathogens, antibiotic-resistant bacterial infections, endotoxemia, and sepsis, which is the leading cause of death in U.S. hospitals. The clinical protocol of first-in-human studies incorporates Sigyn Therapy with regularly scheduled dialysis treatments to address endotoxemia and concurrent inflammation, which are highly prevalent disorders that shorten the lives of end-stage renal disease (ESRD) patients. Extending the lives of those with ESRD could significantly impact dialysis industry revenues.
The Company's oncology pipeline is comprised of ImmunePrep(TM), a platform to enhance the delivery of immunotherapeutic antibodies; ChemoPrep(TM) to improve the delivery of chemotherapeutic agents; and ChemoPure(TM) to reduce chemotherapy toxicity. If successfully advanced, the Company's therapies offer to provide strategic value to the dialysis and biopharmaceutical industry.
To learn more about Sigyn Therapeutics, visit: www.SigynTherapeutics.com
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.